<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326050</url>
  </required_header>
  <id_info>
    <org_study_id>rhinoscleroma</org_study_id>
    <nct_id>NCT03326050</nct_id>
  </id_info>
  <brief_title>Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma</brief_title>
  <official_title>Gemifloxacin Versus Ciprofloxacin Versus Rifampicin in Treatment of Rhinoscleroma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      gemifloxacin versus ciprofloxacin and rifampicin in treatment of rhinoscleroma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rhinoscleroma is a chronic specific granulomatous inflammation affecting nose in 95-100% but
      can affect any part of respiratory tract.(1)

      It is an endemic disease in Egypt. It is endemic as well in sporadic areas worldwide
      including Central America, Chili, Central Africa, India, Indonesia and Middle East
      countries.(2) It is completely eradicated from the developed communities.

      If not treated early, the disease progresses to the final sclerotic phase where permanent
      complications including nasal deformities, anosmia, dysphonia, dysphagia and stridor could
      happen.(3-5)

      Of the wide treatments range (antibiotic combinations, cytostatic drugs, radiation, and
      laser), none is ideal. The causative organism is resistant to most antibiotics and, being
      intracellular, is not always exposed to sufficient concentrations of drug. A clinical cure is
      hard to identify because the end-stage is mucosal fibrosis which, even without active
      infection, interferes with normal function of the upper respiratory tract. The fibrosed
      mucosa, especially in crusts, can become secondarily infected with bacteria, which may
      include klebsiella.(6)

      Rifampin (7), streptomycin (8), ciprofloxacin (5) and levofloxacin (9) have been used in
      treatment of rhinoscleroma.

      Most patients are from a low socioeconomic group and cannot afford the price of antibiotics
      to which klebsiella is susceptible. (6)

      The usual regimen given for free by the Ministry of Health in Egypt in histologically
      positive cases is Rifampicin 300 mg twice daily for six months (based on a nasal biopsy and
      documented as a Tuberculosis, not rhinoscleroma, to allow free delivery of the medication)
      then another biopsy is taken to identify if cure or not. If not, Rifampicin is given for
      another six months and so on.

      Unfortunately, due to the high level of antimicrobial resistance, poor patients' compliance,
      and drugs side effects, the treatment failure rate is increasing. So there is a real need for
      an alternative drug that is effective, safe and has a short treatment course.

      Gemifloxacin is a new fluoroquinolone that has bactericidal activity. It has good
      intracellular penetration and low toxicity.(10) It is more potent than ciprofloxacin,
      ofloxacin and levofloxacin.(11)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical examination., nasal crustation,</measure>
    <time_frame>monthly evaluation for 6 months</time_frame>
    <description>nasal crusting, O= no symptoms, 1 = present monthly 2= present weekly, 3 = present daily, 4 = always present, and 5 = incapacitating). (6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical examination purulent secretions</measure>
    <time_frame>monthly evaluation for 6 months</time_frame>
    <description>purulent secretions (O= no symptoms, 1 = present monthly 2= present weekly, 3 = present daily, 4 = always present, and 5 = incapacitating). (6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>â€¢ Full ENT history</measure>
    <time_frame>monthly evaluation for 6 months</time_frame>
    <description>purulent rhinorrhea, postnasal discharge, nasal crustation, hyposmia, and nasal obstruction</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rhinoscleroma</condition>
  <arm_group>
    <arm_group_label>gemifloxacin and Rifampicin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>first group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once dailygroup will be given the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily for three months..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemifloxacin and ciprofloxacin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>. group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily group will be given a short course (four weeks) of oral Ciprofloxacin 750 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemifloxacin and placipo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>.group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemifloxacin</intervention_name>
    <description>Gemifloxacin 320Mg Oral Tablet once daily</description>
    <arm_group_label>gemifloxacin and Rifampicin</arm_group_label>
    <arm_group_label>gemifloxacin and ciprofloxacin</arm_group_label>
    <arm_group_label>gemifloxacin and placipo</arm_group_label>
    <other_name>Gemifloxacin 320Mg Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>cipro 750 tablet twice daily</description>
    <arm_group_label>gemifloxacin and Rifampicin</arm_group_label>
    <arm_group_label>gemifloxacin and ciprofloxacin</arm_group_label>
    <arm_group_label>gemifloxacin and placipo</arm_group_label>
    <other_name>Cipro 750Mg Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin 150Mg Capsule twice daily</description>
    <arm_group_label>gemifloxacin and Rifampicin</arm_group_label>
    <arm_group_label>gemifloxacin and ciprofloxacin</arm_group_label>
    <arm_group_label>gemifloxacin and placipo</arm_group_label>
    <other_name>Rifampicin 150Mg Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age above 18 years

          2. Active rhinoscleroma proved both clinically and histopathologically

        Exclusion Criteria:

          1. Patients younger than 18 years old.

          2. inactive Rhinoscleroma

          3. Contraindication to treatment severe renal or hepatic impairment

          4. Refusal of enrollment in the research by the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed mohamed, lecturer</last_name>
    <role>Study Director</role>
    <affiliation>assiut yunveristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>asmaa ahmed, resident</last_name>
    <phone>01022091284</phone>
    <email>asmaabakhiet1992@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asmaa Ahmed</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Ahmed AR, El-Badawy ZH, Mohamed IR, Abdelhameed WA. Rhinoscleroma: a detailed histopathological diagnostic insight. Int J Clin Exp Pathol. 2015 Jul 1;8(7):8438-45. eCollection 2015.</citation>
    <PMID>26339415</PMID>
  </results_reference>
  <results_reference>
    <citation>Hart CA, Rao SK. Rhinoscleroma. J Med Microbiol. 2000 May;49(5):395-6.</citation>
    <PMID>10798549</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhong Q, Guo W, Chen X, Ni X, Fang J, Huang Z, Zhang S. Rhinoscleroma: a retrospective study of pathologic and clinical features. J Otolaryngol Head Neck Surg. 2011 Apr;40(2):167-74.</citation>
    <PMID>21453653</PMID>
  </results_reference>
  <results_reference>
    <citation>Fawaz S, Tiba M, Salman M, Othman H. Clinical, radiological and pathological study of 88 cases of typical and complicated scleroma. Clin Respir J. 2011 Apr;5(2):112-21. doi: 10.1111/j.1752-699X.2010.00207.x.</citation>
    <PMID>21410904</PMID>
  </results_reference>
  <results_reference>
    <citation>Bailhache A, Dehesdin D, FranÃ§ois A, Marie JP, Choussy O. Rhinoscleroma of the sinuses. Rhinology. 2008 Dec;46(4):338-41. Review.</citation>
    <PMID>19146007</PMID>
  </results_reference>
  <results_reference>
    <citation>Borgstein J, Sada E, Cortes R. Ciprofloxacin for rhinoscleroma and ozena. Lancet. 1993 Jul 10;342(8863):122.</citation>
    <PMID>8100894</PMID>
  </results_reference>
  <results_reference>
    <citation>Gamea AM, el-Tatawi FA. The effect of rifampicin on rhinoscleroma: an electron microscopic study. J Laryngol Otol. 1990 Oct;104(10):772-7.</citation>
    <PMID>2246576</PMID>
  </results_reference>
  <results_reference>
    <citation>Toppozada HH, Gaafar HA. The effect of streptomycin and irradiation on rhinoscleroma (electron microscopic study). J Laryngol Otol. 1986 Jul;100(7):809-15.</citation>
    <PMID>3734600</PMID>
  </results_reference>
  <results_reference>
    <citation>Pound MW, Fulton KB, Chima CO. Successful treatment of Klebsiella rhinoscleromatis bacteremia with levofloxacin. Pharmacotherapy. 2007 Jan;27(1):161-3.</citation>
    <PMID>17192170</PMID>
  </results_reference>
  <results_reference>
    <citation>Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis. 2003 Nov 1;37(9):1210-5. Epub 2003 Oct 2.</citation>
    <PMID>14557966</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA; Gemifloxacin Surveillance Study Research Group. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microbiol Infect Dis. 2001 May-Jun;40(1-2):51-7.</citation>
    <PMID>11448564</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>asmaa ahmed bekheit</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rhinoscleroma</keyword>
  <keyword>Gemifloxacin</keyword>
  <keyword>Ciprofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinoscleroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Gemifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

